C-type Lectin-like Molecule-1 as a Potential Biomarker for Diagnosis and Prognosis in Acute Myeloid Leukemia

Jinghua Wang, Weida Wang, Hao Chen, Wenmin Li, Tian Huang, Weiya Zhang, Ling Wei, Peilong Lai, Yulian Wang, Suxia Geng, Minming Li, Xin Du, Jianyu WengResearch 2020 · DOI

Abstract

Cytogenetic and molecular genetic abnormalities are critical factors in the prognosis of acute myeloid leukemia (AML), yet patients within the same risk groups often exhibit variable outcomes. Immunophenotyping remains a cornerstone of AML diagnosis due to its simplicity and universal applicability. This study aimed to identify new immunophenotypic markers for the diagnosis and prognosis of AML. We examined the expression of C-type lectin-like molecule 1 (CLL-1) in AML blasts from 52 patients and compared it with classic markers like CD33 and CD34. Our results indicate that CLL-1 is expressed on the majority of AML blasts (78.8%) and leukemic stem cells (LSCs) but is absent on normal hematopoietic stem cells (HSCs). Furthermore, low CLL-1 expression was independently associated with shorter overall survival (OS), identifying CLL-1 as a potent dual-purpose biomarker for AML.

Introduction

Acute Myeloid Leukemia (AML) is a highly heterogeneous malignancy, making it difficult to predict clinical outcomes using current genetic risk profiles alone. Standard diagnostic markers, such as CD33 and CD34, are frequently expressed on both leukemic cells and healthy hematopoietic stem cells (HSCs). This lack of specificity complicates the targeting of "cancer seeds" without damaging the patient's healthy blood-forming capacity. There is an urgent clinical need for markers that can specifically distinguish leukemic stem cells (LSCs) from healthy ones while providing reliable prognostic insights.

Methods

The study analyzed bone marrow or peripheral blood samples from 52 patients with newly diagnosed or relapsed/refractory AML at Guangdong Provincial People's Hospital.

  • Immunophenotyping: Flow cytometry was employed to measure the expression levels of CLL-1, CD33, and CD34 on AML blasts and stem cell populations ($CD34^+CD38^-$).
  • Comparative Analysis: CLL-1 expression was benchmarked against normal bone marrow (NBM) samples and validated using the Human Proteome Map, a public mass spectrometry database, to ensure tissue specificity.
  • Survival Analysis: Patients were categorized into "CLL-1 high" and "CLL-1 low" groups based on a 59.0% expression cutoff. Kaplan-Meier curves and log-rank tests were used to evaluate Event-Free Survival (EFS) and Overall Survival (OS).

Results

A Specific and Synergistic Diagnostic Marker

CLL-1 was found on the surface of 78.8% of AML blasts. Crucially, while CLL-1 is prevalent on leukemic stem cells, it is notably absent on normal hematopoietic stem cells. This makes CLL-1 a "cleaner" target for emerging therapies, such as CAR-T cells, compared to CD33. Additionally, CLL-1 demonstrated diagnostic synergy; it often "filled the gap" in cases where standard markers like CD33 or CD34 were low, increasing overall diagnostic sensitivity.

CLL-1 expression profiles in AML blasts and normal tissues.

The Prognostic Paradox

While higher expression of a cancer marker usually suggests a worse outcome, this study found a prognostic paradox: low CLL-1 expression (≤ 59%) predicted significantly poorer survival.

  • Overall Survival: The CLL-1 low group had significantly shorter OS ($p = 0.012$) and EFS ($p = 0.048$) than the high-expression group.
  • Treatment Resistance: In patients who failed to achieve complete remission after initial treatment, low CLL-1 expression was even more strongly associated with rapid disease progression ($p < 0.001$).

This suggests that the absence of CLL-1 may characterize a more primitive, aggressive, and treatment-resistant phenotype of the disease.

Discussion

These findings identify CLL-1 as a valuable tool for both the diagnosis and long-term management of AML. Its absence on healthy HSCs provides a therapeutic window for targeted treatments, while its expression levels offer a simple, flow-cytometry-based method for predicting patient survival.

However, the study's sample size of 52 patients necessitates larger, multi-center trials to validate the 59% cutoff for clinical use. Future research should also investigate the biological mechanisms—specifically the signaling pathways—that cause low CLL-1 expression to correlate with such aggressive disease progression.

Summary updated

Abstract

Abstract Background Cytogenetic and molecular genetic abnormalities are now considered to be important factors affecting the prognosis of acute myeloid leukemia (AML), while variable outcomes may appear in the same risk group. Immunophenotyping has been the core in AML diagnosis, which is simple and universal application. The aim of this study was to explore and identify new immunophenotypic markers that related to the diagnosis and prognosis of AML. Methods The expression of C type lectin like molecule 1 (CLL‐1) in AML blasts were examined in 52 patients with newly diagnosed or relapsed/refractory AML, and was compared with other classic markers in AML, in order to assess the value of CLL-1 as an independent biomarker or in combination with other markers for diagnosis in AML. Subsequently, we assessed the value of CLL-1 as a biomarker for prognosis in this malignant tumor. Results The results showed that CLL 1 was expressed on the cell surface of the majority of AML blasts (78.8%), and also expressed on leukemic stem cells in varying degree but absent on normal hematopoietic stem cells. Notably, CLL 1 was able to complement the classic markers CD33 or CD34. After dividing the cases into CLL‐1high and CLL‐1low groups according to cutoff 59.0%, we discovered that event free survival and overall survival (OS) of the CLL‐1low group were significantly lower than the CLL‐1high group, and low CLL 1 expression seems to be independently associated with shorter OS. Conclusions These data identified CLL 1 as a potential biomarker for diagnosis and prognosis of AML.
BibTeX
@inproceedings{wang2020c,
  author = {Jinghua Wang and Weida Wang and Hao Chen and Wenmin Li and Tian Huang and Weiya Zhang and Ling Wei and Peilong Lai and Yulian Wang and Suxia Geng and Minming Li and Xin Du and Jianyu Weng},
  title = {{C-type Lectin-like Molecule-1 as a Potential Biomarker for Diagnosis and Prognosis in Acute Myeloid Leukemia}},
  booktitle = {Research},
  year = {2020},
  doi = {10.21203/rs.3.rs-73081/v1},
}
Figure